Posts by cowic

            The 62005 study looked at the ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. Results Study 62005

Cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib. Trial name: CABO-GIST (see more information on our study registry) Agents: Cabozantinib Phase: II Status: Open, recruiting Sponsor: European Organisation for Research and Treatment of Cancer – EORTC Further information https://clinicaltrials.gov/ct/show/NCT02216578 or http://www.eortc.org/clinical-trials/

    Newly established European Reference Networks (ERNs) start their work March 1, 2017 24 thematic ERNs, gathering over 900 highly specialised healthcare units from 26 countries, will begin working together on a wide range of issues. Among them the ERN for Rare Solid Tumours EURACAN. SPAEN, along with other patient advocacy groups for rare…

On 8th of February 2017 a rare cancer policy debate at the European Parliament took place on how to improve the policy response to rare cancers, with a focus on sarcoma. Representatives from the ​European ​Commission, ​Member States, the ​European ​Parliament,  ​industry ​delegates and ​sarcoma ​patients engaged in a policy debate on key challendes for…

On the 15th and 16th of November 2016, 50 surgeons from 13 different countries met in Institut Curie, Paris to attend the fifth edition of the esurge sarcoma surgery masterclass developed and directed by Dr Sylvie Bonvalot (Institut Curie) and Dr Alessandro Gronchi (Istituto di Tumori di Milano). Launched in 2010 as part of the…

Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (SUNRISELMS) Agents: Unesbulin in combination with dacabazine Phase II/III Status  Recruiting Sponsor PTC Therapeutics Further information: https://clinicaltrials.gov/ct2/show/NCT05269355 This study compares the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in patients with unresectable or metastatic, relapsed or refractory leiomyosarcoma (LMS) who have received at…